Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio5.27
Quick Ratio5.27
Price-To-Earnings
Trailing P/E Ratio-6.31
Forward P/E Ratio-3.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.95 million
Price / Sales7.32
Cash FlowN/A
Price / CashN/A
Book Value$4.24 per share
Price / Book1.25
Profitability
EPS (Most Recent Fiscal Year)($0.84)
Net Income$-27,820,000.00
Net Margins-131.51%
Return on Equity-22.92%
Return on Assets-17.93%
Miscellaneous
Employees73
Outstanding Shares35,850,000
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences Inc (NASDAQ:CALA) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.05. The biotechnology company had revenue of $5.19 million for the quarter, compared to the consensus estimate of $7.28 million. Calithera Biosciences had a negative net margin of 131.51% and a negative return on equity of 22.92%. View Calithera Biosciences' Earnings History.
What price target have analysts set for CALA?
3 equities research analysts have issued 12 month price objectives for Calithera Biosciences' stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Calithera Biosciences' stock price to reach $14.00 in the next twelve months. View Analyst Ratings for Calithera Biosciences.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include CannTrust (CNTTF), Odonate Therapeutics (ODT), Adamas Pharmaceuticals (ADMS), Geron (GERN), GlycoMimetics (GLYC), Dicerna Pharmaceuticals (DRNA), Aduro BioTech (ADRO), Progenics Pharmaceuticals (PGNX), Akebia Therapeutics (AKBA), Keryx Biopharmaceuticals (KERX), Kura Oncology (KURA), Viking Therapeutics (VKTX), Aclaris Therapeutics (ACRS), Five Prime Therapeutics (FPRX) and ChemoCentryx (CCXI).
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Dr. Susan M. Molineaux, Co-Founder, CEO, Pres, Principal Financial Officer & Director (Age 64)
- Dr. Keith Orford M.D., Ph.D., Sr. VP of Clinical Devel. (Age 46)
- Ms. Stephanie Wong, Sr. VP of Fin., Sec. & Principal Accounting Officer (Age 44)
- Ms. Jennifer McNealey, VP of Investor Relations & Strategy
- Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer
Has Calithera Biosciences been receiving favorable news coverage?
News stories about CALA stock have been trending positive on Friday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Calithera Biosciences earned a news impact score of 0.26 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.39 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Calithera Biosciences' major shareholders?
Calithera Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.01%), Federated Investors Inc. PA (3.97%), American Century Companies Inc. (2.22%), Millennium Management LLC (1.99%), Franklin Resources Inc. (1.79%) and Dimensional Fund Advisors LP (1.32%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.
Which major investors are selling Calithera Biosciences stock?
CALA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Franklin Resources Inc. and Barclays PLC. Company insiders that have sold Calithera Biosciences company stock in the last year include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Insider Buying and Selling for Calithera Biosciences.
Which major investors are buying Calithera Biosciences stock?
CALA stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, BlackRock Inc., Dimensional Fund Advisors LP, American Century Companies Inc., GSA Capital Partners LLP, Candriam Luxembourg S.C.A., Alambic Investment Management L.P. and Dynamic Technology Lab Private Ltd. View Insider Buying and Selling for Calithera Biosciences.
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $5.30.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $178.33 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
